Company intelligence / Profile preview
Sarepta Therapeutics
Cambridge, Massachusetts, USAsarepta.com ↗
- Ownership
- Public · SRPT
- Development stage
- Other
01
Overview
Sarepta Therapeutics has four FDA-approved therapies for Duchenne muscular dystrophy—Exondys 51, Vyondys 53, Amondys 45, and Elevidys—with Elevidys being the first gene therapy approved for DMD. The company’s pipeline includes over forty programs targeting rare neuromuscular diseases using RNA-targeted drugs and gene therapies. In recent years it has achieved significant revenue growth ($1.79 billion in preliminary net product revenue for FY2024) and expanded its reach through key partnerships with Roche and Arrowhead Pharmaceuticals[2][5][6].
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- RNA-targeted therapeutics (phosphorodiamidate morpholino oligomers/PMOs)Gene therapy (AAV-based)Gene editing
- Industry
- Biotech
02
Drug pipeline
44 assets43 more assets in the full pipeline.
03
Partnerships
Roche (exclusive rights to commercialize ELEVIDYS outside the US)[6]Arrowhead Pharmaceuticals (siRNA collaboration)[2]Thermo Fisher Scientific, Catalent, Aldevron (manufacturing partners)[6]
04
Financials
- Market cap
- $1.9B
- Total revenue
- $2.2B
- Enterprise value
- $2B
Beyond the preview
Go deeper on Sarepta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sarepta Therapeutics.